Each year, roughly the same numbers of boys and girls are born.
FDA Greenlights Imaging Agent to Detect Residual Cancer After Lumpectomy
The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with
April 19, 2024